Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 23, 2009
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009 ReGen Biologics to Present at Canaccord Adams Musculoskeletal Conference Prior to AAOS Annual Meeting
HACKENSACK, N.J.--([ BUSINESS WIRE ])--ReGen Biologics (OTC: RGBO) ("ReGen" or the "Company"), an orthopedic products company with a meniscus repair device that recently received FDA clearance, announced it will present at the Canaccord Adams Musculoskeletal Conference on Tuesday, February 24 at the University of Nevada in Las Vegas. Gerald E. Bisbee, Jr., Ph.D., the Company's Chairman and CEO, will make the presentation at 10:40 a.m. (PST). A copy of the presentation will be available on the Company's website at [ www.regenbio.com ] following the meeting.
The conference precedes the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS), also taking place in Las Vegas that week. ReGen will host an exhibit at the AAOS Annual Meeting for the U.S. introduction of the recently 510(k) cleared Menaflex™ collagen meniscus implant. The Company's booth will be located in Hall A, Booth #629.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first approved product using its proprietary biological collagen scaffold technology is the Menaflex™ collagen meniscus implant, which is cleared for sale in Europe and other countries and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen received FDA clearance in the U.S. for the Menaflex device in December 2008. Visit [ www.regenbio.com ] and [ www.menaflex.com ] for more information.
This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of ReGen management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2007 annual report on Form 10-K, its most recently issued quarterly report filed on Form 10-Q and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at [ www.regenbio.com ], from commercial document-retrieval services and at the website maintained by the SEC at [ www.sec.gov ].
